ImmunOs Therapeutics AG raises US$11m in Series C financing

ImmunOs Therapeutics AG said it will use the proceeds to advance the ongoing clinical trial of ImmunOs’ lead program IOS-1002 to completion of the Phase Ia dose escalation study as a monotherapy and in combination with MSD’s anti-PD-1 antibody pembrolizumab. IOS-1002 is a novel, multifunctional immunotherapy agent for the treatment of advanced solid tumours that simultaneously targets several immune checkpoints. It is based on a naturally occurring human leukocyte antigen (HLA) targeting LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1 and designed to activate both innate and adaptive immune cells to modulate the tumour microenvironment, potentially boosting the reach of existing immunoncological treatments such as pembrolizumab.

ImmunOs’ lead program is a multi-functional HLA-fusion protein that binds specific LILRB (leukocyte immunoglobulin-like) and KIR (killer cell immunoglobulin-like) receptors that was shown to stimulate both the innate and the adaptive immune systems of cancer patients to eliminate tumour cells. ImmunOs is also developing different modalities to agonise receptors for the modulation of the immune system in autoimmune diseases.

ImmunOs Therapeutics is committed to advancing the clinical development of IOS-1002 and exploring its potential to improve the lives of cancer patients.